Approximately one-third of adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) had a survival of at least 30 months in a study where they were administered blinatumomab, according to an article published online ahead of print in Blood.1
Investigators conducted a long-term follow-up analysis on overall survival and relapse-free survival in a phase 2 study of 36 adults with relapsed/refractory ALL who were treated with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab.
Primary analysis revealed that 69% of patients achieved complete remission with full (CR) or partial (CRh) recovery of peripheral blood counts within the first 2 cycles.
Continue Reading
Minimal residual disease (MRD) response (<10-4 blasts) was achieved in 25 (69%) of patients, with 22 achieving CR/CRh.
Median overall survival was 13.0 months. A total of 10 (28%) of patients were long-term survivors, with an overall survival ≥30 months. Long-term survival was associated with MRD, T-cell expansion, and B cell depletion.
RELATED: Inotuzumab Ozogamicin Granted Breakthrough Therapy Designation for Acute Leukemia
Median relapse-free survival was 8.8 months, with a median follow-up of 28.9 months.
In regard to safety, three long-term survivors experienced neurologic events or cytokine release syndrome that resulted in temporary treatment discontinuation.
Reference
- Zugmaier G, Gӧkbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in adult patients with relapsed/refractory B-precursors acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE® antibody construct blinatumomab [published onhile ahead of print October 19, 2015]. Blood. doi: 10.1182/blood-2015-06-649111.
